A New Target for Preventing Glucocorticoid-Induced Fractures in Inflammatory Conditions
A major study in Arthritis & Rheumatology provides critical data on preventing glucocorticoid harms, a common challenge in critical care and inflammatory disease management. Using a target trial approach with data from over 40,000 patients with polymyalgia rheumatica, researchers found that prescribing bisphosphonates was associated with a significant reduction in fragility fractures. Specifically, 1.40% of patients on a 12-month bisphosphonate regimen experienced a fracture, compared to 2.32% of those not prescribed the medication, translating to a number needed to treat of 109. The study also revealed that prescribing gastroprotective medications like proton-pump inhibitors was not associated with a reduced risk of serious gastrointestinal ulceration or bleeding events in this population.
Study Significance: For critical care and ICU professionals managing patients on long-term glucocorticoids for conditions like sepsis-related inflammation or post-transplant care, this evidence strengthens the case for proactive bone protection. The clear fracture risk reduction supports integrating bisphosphonate assessment into standard protocols for patients requiring sustained steroid therapy. Conversely, the findings on gastroprotection suggest an opportunity to deprescribe unnecessary medications, aligning with antimicrobial and sedation stewardship principles to reduce polypharmacy and potential adverse drug interactions in complex ICU patients.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
